Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 27 Jan 2017 |
| Publishing of Orion Corporation's Financial Statement Release for 2016 on 8 February 2017 | 25 Jan 2017 |
| Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2017 AGM of Orion Corporation | 24 Jan 2017 |
| 87,000 Orion Corporation A shares converted into B shares | 22 Dec 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 15 Dec 2016 |
| 100,000 Orion Corporation A shares converted into B shares | 18 Nov 2016 |